Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin T Nguyen

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Surgery|March 19, 2013
Recurrence after operative management of intrahepatic cholangiocarcinomaOmar Hyder, Ioannis Hatzaras, Georgios C Sotiropoulos, et al.
Surgical Endoscopy|September 11, 2025
Postoperative outcomes with minimally invasive minor hepatectomy based on ECOG performance status - analysis of multi-institutional databaseParit T Mavani, Subir Goyal, Melissa E Hogg, et al.
Journal of Diabetes Science and Technology|October 4, 2021
Continuous Ketone Monitoring Consensus Report 2021Kevin T Nguyen, Nicole Y Xu, Jennifer Y Zhang, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessmentMechteld C de Jong, Hari Nathan, Georgios C Sotiropoulos, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Chemmedchem|March 12, 2015
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325Michael T Rudd, John W Butcher, Kevin T Nguyen, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorSteven Harper, John A McCauley, Michael T Rudd, et al.
Journal of Diabetes Science and Technology|March 29, 2022
A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician RatingsDavid C Klonoff, Jing Wang, David Rodbard, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Surgery|March 19, 2013
Recurrence after operative management of intrahepatic cholangiocarcinomaOmar Hyder, Ioannis Hatzaras, Georgios C Sotiropoulos, et al.
Surgical Endoscopy|September 11, 2025
Postoperative outcomes with minimally invasive minor hepatectomy based on ECOG performance status - analysis of multi-institutional databaseParit T Mavani, Subir Goyal, Melissa E Hogg, et al.
Journal of Diabetes Science and Technology|October 4, 2021
Continuous Ketone Monitoring Consensus Report 2021Kevin T Nguyen, Nicole Y Xu, Jennifer Y Zhang, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessmentMechteld C de Jong, Hari Nathan, Georgios C Sotiropoulos, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Chemmedchem|March 12, 2015
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325Michael T Rudd, John W Butcher, Kevin T Nguyen, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorSteven Harper, John A McCauley, Michael T Rudd, et al.
Journal of Diabetes Science and Technology|March 29, 2022
A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician RatingsDavid C Klonoff, Jing Wang, David Rodbard, et al.
Pageof 4